MSC Immunomodulatory Assessment via CD54 and IL-6 Markers

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods lack a standardized approach to assess the immunomodulatory potential of multipotent stromal cell (MSC) populations, which is crucial for their therapeutic applications in autoimmune and inflammatory diseases, as the immunomodulatory potential can vary based on tissue origin and culture conditions.

Innovation Solution

Evaluating the amount of CD54/IL-6 associated with MSCs using detectable labels and flow cytometry to assess the immunomodulatory potential, providing a quantitative or qualitative assessment based on the CD54/IL-6 result, and using systems and kits for practicing these methods.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If MSC populations are expanded in vitro from different tissues and culture conditions, then the quantity of MSCs increases, but the immunomodulatory potential varies and becomes less reliable

Engineering Contradiction:

ImproveMSC expansion quantityVSAvoidimmunomodulatory potential consistency

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent changes the assessment parameters from general MSC characterization to specific immunomodulatory markers (CD54, IL-6, IDO, CD274) to reliably evaluate immunomodulatory potential despite variations in tissue origin and culture conditions

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent implements a feedback mechanism by assessing MSC populations for specific immunomodulatory markers and using this information to select or optimize MSC preparations with enhanced and consistent immunomodulatory potential for therapeutic applications

Inventive Principle:

Principle #23Feedback

2Ease of operation

If traditional MSC assessment methods are used, then the evaluation process is simple, but the assessment lacks precision in determining immunomodulatory potential

Engineering Contradiction:

Improveassessment simplicityVSAvoidimmunomodulatory potential assessment accuracy

Core Design Contradiction:

Ease of operationVSMeasurement precision

Solution Approach 1:

The patent replaces traditional functional assays with flow cytometry-based detection of surface markers and cytokine expression, substituting complex mechanical/functional testing with optimized optical detection methods that maintain ease of operation while significantly improving measurement precision

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent uses fluorescently labeled antibodies that bind to specific MSC markers (CD54, IL-6, IDO, CD274), detecting immunomodulatory potential through color/fluorescence intensity changes measured by flow cytometry, providing precise quantification while maintaining operational simplicity

Inventive Principle:

Principle #32Color changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach allows for a reliable evaluation of MSC populations, enabling the identification of those with enhanced immunomodulatory potential, which is critical for therapeutic applications, such as treating autoimmune and inflammatory diseases, by quantifying CD54 and IL-6 expression levels.

Implementation Method 1

evaluating the amount of CD54/IL-6 associated with an MSC in a sample of the MSC population using detectable labels

Methodology Applied

Scientific EffectAntibody-antigen binding:

Data Source

PatentUS9632096B2Methods of assessing the immunomodulatory potential of a multipotent stromal cell (MSC) population, and systems and kits for practicing the same

Publication Date: 2017.04.25 BECTON DICKINSON & CO

AI summary

Methods of assessing the immunomodulatory potential of a multipotent stromal cell (MSC) population are provided. Aspects of the methods include evaluating the amount of CD54/IL-6 associated with an MSC in a sample of the MSC population to obtain a CD54/IL-6 result and providing an assessment of the immunomodulatory potential of the MSC population based on the obtained CD54/IL-6 result. Also provided are systems and kits that find use in practicing the subject methods.